tickdelta
Sign in
Tables

Tables in the 10-Q of INSULET CORP

37 tables with numbers, filed May 6, 2026. Each one downloads as an Excel file or a CSV (numbers are stored as numbers), with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

← Filings of PODD

Table 1 after “TABLE OF CONTENTS”

PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (Unaudited)3
Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2026 and December 31, 20253
Condensed Consolidated Statements of Income (Unaudited) for the three months ended March 31, 2026 and 20254
Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three months ended March 31, 2026 and 20255
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three months ended March 31, 2026 and 20256
Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2026 and 20257
Notes to Condensed Consolidated Financial Statements (Unaudited)8

First 8 of 20 rows. The download has all of them.

Table 2 after “(UNAUDITED)”

(in millions, except share and per share data)March 31, 2026December 31, 2025
ASSETS
Current Assets
Cash and cash equivalents$480.4$716.1
Accounts receivable trade, net544.7516.9
Inventories462.5452.6
Prepaid expenses and other current assets221.9228.3
Total current assets1,709.51,914.0

First 8 of 33 rows. The download has all of them.

Table 3 after “(UNAUDITED)”

Three Months Ended March 31,
(in millions, except share and per share data)20262025
Revenue$761.7$420.5
Revenue from related party—148.5
Total revenue761.7569.0
Cost of revenue232.7159.9
Gross profit529.1409.0
Research and development expenses89.759.6

First 8 of 23 rows. The download has all of them.

Table 4 after “(UNAUDITED)”

Three Months Ended March 31,
(in millions)20262025
Net income$91.1$35.4
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment(6.6)10.3
Unrealized loss on cash flow hedges, net of tax(0.3)(3.1)
Other comprehensive (loss) income, net of tax(6.9)7.2
Comprehensive income$84.2$42.6

Table 5 after “Three Months Ended March 31, 2026”

Common StockAdditional Paid-in CapitalAccumulatedEarningsAccumulated Other Comprehensive IncomeTreasury StockDeferred CompensationTotal Shareholders’ Equity
(dollars in millions)Shares (in thousands)Amount
Balance at December 31, 202570,391$0.1$1,274.9$287.4$12.5$(60.4)$0.8$1,515.2
Net income———91.1———91.1
Other comprehensive loss, net of tax————(6.9)——(6.9)
Exercise of options to purchase common stock5—0.4————0.4
Stock-based compensation expense——21.3————21.3
Restricted stock units vested, net of shares withheld for taxes118—(15.7)————(15.7)

First 8 of 11 rows. The download has all of them.

Table 6 after “Three Months Ended March 31, 2025”

Common StockAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive (Loss) IncomeTreasury StockDeferred CompensationTotal Shareholders’ Equity
(dollars in millions)Shares (in thousands)Amount
Balance at December 31, 202470,196$0.1$1,184.4$40.3$(13.2)$—$—$1,211.6
Net income———35.4———35.4
Other comprehensive income, net of tax————7.2——7.2
Exercise of options to purchase common stock38—2.5————2.5
Stock-based compensation expense——18.2————18.2
Restricted stock units vested, net of shares withheld for taxes128—(21.2)————(21.2)

First 8 of 11 rows. The download has all of them.

Table 7 after “(UNAUDITED)”

Three Months Ended March 31,
(in millions)20262025
Cash flows from operating activities
Net income$91.1$35.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization26.221.7
Stock-based compensation expense21.318.2
Non-cash interest expense0.72.5

First 8 of 41 rows. The download has all of them.

Table 8 after “The following table summarizes the Company’s disaggregated revenue:”

Three Months Ended March 31,
(in millions)20262025
U.S.$515.6$401.7
International242.9152.3
Total Omnipod products758.4554.0
Drug Delivery3.314.9
Total revenue$761.7$569.0

Table 9 after “The percentages of total revenue for customers that represent 10% or more of total revenue were as follows:”

Three Months Ended March 31,
20262025
Distributor A21%25%
Distributor B25%24%
Distributor C19%23%

Table 10 after “Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amo”

(in millions)March 31, 2026December 31, 2025
Accrued expenses and other current liabilities$12.1$14.0
Other liabilities1.81.5
Total deferred revenue$14.0$15.5

Table 11 after “Revenue recognized from amounts included in deferred revenue at the beginning of each respective period was as follows:”

Three Months Ended March 31,
(in millions)20262025
Deferred revenue recognized$6.4$5.6

Table 12 after “Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the fo”

(in millions)March 31, 2026December 31, 2025
Prepaid expenses and other current assets$25.4$25.3
Other assets51.753.0
Total capitalized contract acquisition costs, net$77.1$78.4

Table 13 after “Accounts receivable, net were comprised of the following:”

(in millions)March 31, 2026December 31, 2025
Accounts receivable trade, net$542.1$511.3
Unbilled receivable2.55.7
Accounts receivable, net$544.7$516.9

Table 14 after “The percentages of accounts receivable trade for customers that represent 10% or more of total accounts receivable trade were as follows:”

March 31, 2026December 31, 2025
Distributor A28%37%
Distributor B26%20%
Distributor C12%10%

Table 15 after “Inventories were comprised of the following:”

(in millions)March 31, 2026December 31, 2025
Raw materials$212.6$194.1
Work in process77.964.6
Finished goods172.0193.9
Total inventories$462.5$452.6

Table 16 after “Capitalized costs to implement cloud computing arrangements at cost and accumulated amortization were as follows:”

(in millions)March 31, 2026December 31, 2025
Short-term portion$46.4$46.0
Long-term portion174.3159.1
Total capitalized implementation costs220.7205.1
Less: accumulated amortization(105.9)(94.4)
Capitalized implementation costs, net$114.8$110.7

Table 17 after “The gross carrying amount, accumulated amortization and net book value of intangible assets at the end of each period were as follows:”

March 31, 2026December 31, 2025
(in millions)Gross Carrying AmountAccumulated AmortizationNet Book ValueGross Carrying AmountAccumulated AmortizationNet Book Value
Customer relationships$43.2$(36.3)$6.9$43.2$(35.8)$7.4
Internal-use software71.4(17.1)54.368.3(14.1)54.2
Developed technology28.3(7.4)20.828.3(6.9)21.4
Patents44.0(10.8)33.244.0(9.9)34.2
Total intangible assets$186.8$(71.7)$115.2$183.8$(66.7)$117.1

Table 18 after “The components of accrued expenses and other current liabilities were as follows:”

(in millions)March 31, 2026December 31, 2025
Accrued rebates$211.3$205.5
Employee compensation and related costs115.0209.2
Professional and consulting services57.658.2
Other135.1113.9
Accrued expenses and other current liabilities$519.0$586.7

Table 19 after “Reconciliations of the changes in the Company’s product warranty liability were as follows:”

Three Months Ended March 31,
(in millions)20262025
Product warranty liability at beginning of period$16.8$13.9
Warranty expense14.27.6
Warranty fulfillment(6.2)(5.4)
Product warranty liability at the end of period$24.7$16.1

Table 20 after “The components of debt consisted of the following:”

March 31, 2026December 31, 2025
(in millions)Maturity DateAmountAmount
Equipment financings202831.634.9
Costa Rica plant financing20283.0—
Revolving Credit Facility2030——
Term Loan B2031476.3477.5
Senior Unsecured Notes2033450.0450.0
Unamortized debt discount(3.5)(3.5)

First 8 of 12 rows. The download has all of them.

Table 21 after “The following tables provide a summary of the significant financial instruments that are disclosed at fair value on a recurring basis:”

Fair Value Measurements at March 31, 2026
(in millions)Level 1Level 2Level 3Total
Term Loan B(1)$479.8$—$—$479.8
Senior Unsecured Notes(1)459.3——459.3
Equipment financings(2)——31.531.5
Costa Rica plant financing(2)——3.03.0
Total$939.1$—$34.5$973.6

Table 22 after “Table of Contents”

Fair Value Measurements at December 31, 2025
(in millions)Level 1Level 2Level 3Total
Term Loan B(1)$482.3$—$—$482.3
Senior Unsecured Notes(1)469.2——469.2
Equipment financings(2)——34.834.8
Total$951.4$—$34.8$986.2

Table 23 after “Geographic information about revenue, based on customer location, is as follows:”

Three Months Ended March 31,
(in millions)20262025
U.S.$518.8$416.6
International242.9152.3
Total revenue$761.7$569.0

Table 24 after “Geographic information about long-lived assets, net, excluding goodwill and other intangible assets is as follows:”

(in millions)March 31, 2026December 31, 2025
U.S.$469.3$472.5
Malaysia224.7220.0
Other136.4126.9
Total long-lived assets, net$830.4$819.5

Table 25 after “Compensation expense related to stock-based awards was recorded as follows:”

Three Months Ended March 31,
(in millions)20262025
Cost of revenue$0.2$0.2
Research and development expenses3.32.6
Selling, general and administrative expenses17.715.4
Total$21.3$18.2

Table 26 after “The computation of basic and diluted earnings per share was as follows:”

Three Months Ended March 31,
(in millions, except share and per share data)20262025
Net income$91.1$35.4
Add back interest expense, net of tax—1.7
Net income, diluted$91.1$37.2
Weighted average number of common shares outstanding, basic (in thousands)69,98670,272
Convertible Senior Notes—3,479
Restricted stock units163231

First 8 of 13 rows. The download has all of them.

Table 27 after “The number of common share equivalents excluded from the computation of diluted earnings per share because either the effect would have been”

Three Months Ended March 31,
(in thousands)20262025
Restricted stock units556422
Stock options207137
Total764560

Table 28 after “Changes in the components of accumulated other comprehensive income (loss), net of tax, were as follows:”

Three Months Ended March 31, 2026
(in millions)Foreign Currency Translation AdjustmentUnrealized Loss on SecuritiesUnrealized Gain on Cash Flow HedgesAccumulated Other Comprehensive Income
Balance at beginning of period$7.5$(0.3)$5.3$12.5
Other comprehensive income (loss) before reclassifications(6.6)—(4.5)(11.2)
Amounts reclassified to net income (1)——4.24.2
Balance at the end of period$0.8$(0.3)$5.0$5.6

Table 29 after “Changes in the components of accumulated other comprehensive income (loss), net of tax, were as follows:”

Three Months Ended March 31, 2025
(in millions)Foreign Currency Translation AdjustmentUnrealized Loss on SecuritiesUnrealized Gain on Cash Flow HedgesAccumulated Other Comprehensive Loss
Balance at beginning of period$(22.3)$(0.3)$9.4$(13.2)
Other comprehensive income (loss) before reclassifications10.3—(8.5)1.8
Amounts reclassified to net income (1)——5.35.3
Balance at the end of period$(12.0)$(0.3)$6.3$(6.0)

Table 30 after “Revenue”

Three Months Ended March 31,
(dollars in millions)20262025Percent ChangeCurrency ImpactConstant Currency(1)
U.S.$515.6$401.728.3%—%28.3%
International242.9152.359.4%14.2%45.2%
Total Omnipod Products758.4554.036.9%3.9%33.0%
Drug Delivery3.314.9(77.9)%—%(77.9)%
Total$761.7$569.033.9%3.8%30.1%

Table 31 after “Costs and Expenses”

Three Months Ended March 31,
20262025
(dollars in millions)AmountPercent of RevenueAmountPercent of Revenue
Cost of revenue$232.730.5%$159.928.1%
Research and development expenses$89.711.8%$59.610.5%
Selling, general and administrative expenses$317.241.6%$260.745.8%

Table 32 after “The table below presents reconciliations of Adjusted EBITDA, a non-GAAP financial measure, to net income, the most directly comparable finan”

Three Months Ended March 31,
(in millions)20262025
Net income$91.1$35.4
Interest expense (income), net9.8(1.1)
Income tax expense21.912.7
Depreciation and amortization26.221.7
Stock-based compensation expense21.318.2
Loss on extinguishment of debt(1)—39.5

First 8 of 12 rows. The download has all of them.

Table 33 after “Summary of Cash Flows”

Three Months Ended March 31,
(in millions)20262025
Cash provided by (used in):
Operating activities$113.8$63.8
Investing activities(27.7)(15.6)
Financing activities(319.9)277.7
Effect of exchange rate changes on cash and cash equivalents(1.9)3.8
Net (decrease) increase in cash and cash equivalents$(235.7)$329.7

Table 34 after “A reconciliation between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow is as follows:”

Three Months Ended March 31,
(in millions)20262025
Net cash provided by operating activities$113.8$63.8
Capital expenditures(24.3)(12.3)
Free cash flow$89.5$51.6

Table 35 after “The following table contains several key measures to gauge our financial condition and liquidity at the end of each period:”

(dollars in millions)March 31, 2026December 31, 2025
Cash and cash equivalents$480.4$716.1
Current portion of long-term debt$18.6$18.4
Long-term debt, net$929.5$930.8
Total debt, net$948.1$949.2
Total stockholders’ equity$1,302.6$1,515.2
Debt-to-total capital ratio42%39%
Net debt-to-total capital ratio21%9%

Table 36 after “The following table presents information regarding repurchases of our shares of common stock during the three months ended March 31, 2026:”

Fiscal PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (1)Total Number of Shares Purchased as a Part of Publicly Announced ProgramMaximum Dollar Value of Shares that May Yet Be Purchased Under the Program (in millions)
1/1/2026 - 1/31/2026$—$—$—$415.4
2/1/2026 - 2/28/2026$992,186$241.89$992,186$175.4
3/1/2026 - 3/31/2026$258,358$232.15$258,358$115.4

Table 37 after “Item 6. Exhibits”

NumberDescription
10.1*#Separation Agreement between Insulet Corporation and Ana Chadwick, dated February 10, 2026.
10.2*#Offer Letter between Michael Panos and Insulet Corporation, dated March 9, 2026.
31.1*Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
31.2*Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
32.1**Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer and Chief Financial Officer.
101The following materials from Insulet Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 formatted in iXBRL (Inline eXtensible Business Reporting Language), as follows:
(i) Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2026 and December 31, 2025

First 8 of 16 rows. The download has all of them.